EWTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
EWTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Edgewise Therapeutics's Forward PE Ratio for today is 0.00.
Edgewise Therapeutics's PE Ratio without NRI for today is 0.00.
Edgewise Therapeutics's PE Ratio (TTM) for today is 0.00.
The historical data trend for Edgewise Therapeutics's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edgewise Therapeutics Annual Data | |
Trend | |
Forward PE Ratio |
Edgewise Therapeutics Quarterly Data |
Forward PE Ratio |
For the Biotechnology subindustry, Edgewise Therapeutics's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Edgewise Therapeutics's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Edgewise Therapeutics's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Edgewise Therapeutics (NAS:EWTX) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Thank you for viewing the detailed overview of Edgewise Therapeutics's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Alan J Russell | director, officer: Chief Scientific Officer | 3415 COLORADO AVE, BOULDER CO 80303 |
Kevin Koch | director, officer: President and CEO | 3200 WALNUT ST, BOULDER CO 80301 |
Behrad Derakhshan | officer: Chief Business Officer | 3415 COLORADO AVE., BOULDER CO 80303 |
Joanne M. Donovan | officer: CMO | C/O CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQ. BLDG. 1400E SUITE B14202, CAMBRIDGE MA 02139 |
Marc Semigran | officer: Chief Development Officer | C/O MYOKARDIA, INC., 333 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080 |
John R Moore | officer: General Counsel | 3200 WALNUT ST, BOULDER CO 80301 |
R Michael Carruthers | officer: Chief Financial Officer | 3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301 |
Orbimed Advisors Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Peter A. Thompson | director, 10 percent owner | C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545 |
Jonathan C Fox | director | C/O MYOKARDIA, INC., 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Novo Holdings A/s | 10 percent owner | TUBORG HAVNEVEJ 19, HELLERUP G7 2900 |
Orbimed Capital Gp Vi Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Orbimed Genesis Gp Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Jonathan D Root | director | 2735 SAND HILL ROAD, MENLO PARK CA 94025 |
James E Flynn | 10 percent owner, other: Possible Member of 10% Group | 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
From GuruFocus
By GuruFocus News • 02-14-2025
By Business Wire • 01-07-2025
By Business Wire • 05-07-2024
By Business Wire • 12-05-2024
By GuruFocus News • 11-13-2024
By GuruFocus News • 12-16-2024
By Business Wire • 01-22-2025
By GuruFocus News • 01-13-2025
By Business Wire • 11-07-2024
By GuruFocus Research • 05-10-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.